NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Quantum BioPharma's MS Imaging Study Midpoint Milestone FAQ
Quantum BioPharma (QNTM) announced that patient enrollment in its collaborative imaging study with Massachusetts General Hospital (MGH) for the multiple sclerosis drug candidate Lucid-MS has reached the halfway point. Early imaging results show a robust signal in acute MS lesions and potential sensitivity to gray matter lesions, supporting further development.
Quantum BioPharma announced that patient enrollment in its collaborative imaging study with Massachusetts General Hospital (MGH) for its multiple sclerosis drug candidate Lucid-MS has reached the halfway point.
Reaching the halfway point in patient enrollment is a key milestone in clinical studies, as it indicates progress toward generating reliable evidence on the safety and effectiveness of the diagnostic technology or drug.
Preliminary analyses show a robust signal in acute MS lesions and potential sensitivity to gray matter lesions.
The imaging study is a collaboration between Quantum BioPharma and Massachusetts General Hospital (MGH).
Clinical studies are designed to answer whether a new drug or diagnostic technology works as intended, is safe, and can reliably detect conditions, ensuring that laboratory discoveries can become viable treatments.
More information is available in the company’s newsroom at https://ibn.fm/QNTM and the full article at the provided link.
Lucid-MS is Quantum BioPharma's drug candidate for multiple sclerosis, which is being evaluated in the imaging study with MGH.